ARA-290

10mg vial – high does ensure to reconstitute with extra acetic acid solution.

ARA-290 (Cibinetide) is a synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO), designed to deliver potent anti-inflammatory and cytoprotective effects without stimulating erythropoiesis. By selectively activating the innate repair receptor (IRR), ARA-290 modulates inflammatory pathways, reduces tissue damage, and promotes cellular repair while avoiding the hematologic side effects associated with EPO.

ARA-290 has demonstrated promising activity in preclinical and clinical studies across a range of inflammatory and neuropathic conditions, including small fiber neuropathy, sarcoidosis-related symptoms, and metabolic-associated inflammatory disorders. Its mechanism of action supports reduced cytokine production, improved nerve function, and enhanced tissue resilience under conditions of chronic inflammation.

With a favorable safety profile and targeted biological activity, ARA-290 represents a novel therapeutic approach for diseases driven by inflammation and nerve injury, offering potential benefits where traditional anti-inflammatory or analgesic therapies fall short.

ARA-290 is provided strictly for laboratory, in vitro, and analytical research only and is not approved for human or veterinary use, diagnostic procedures, or therapeutic applications. Any handling, storage, and disposal should follow standard laboratory safety protocols appropriate for experimental peptide reagents.